Literature DB >> 25908111

Improving adherence rate of extended prophylaxis for venous thromboembolic disease after abdominal and pelvic oncologic surgery: a pilot educational study.

Fernando Javier Vázquez1, María Soledad Bilbao2, Javier Saimovici3, Carlos Vaccaro2.   

Abstract

BACKGROUND: Venous thromboembolic disease (VTE) is higher among patients with cancer. For those undergoing abdominal or pelvic surgery for cancer, it is suggested to extend thromboprophylaxis during 4 weeks with low-molecular-weight heparin over limited-duration of 7 days. There is no published local data from our country about compliance with recommended guidelines of extended prophylaxis (EP) in patients with cancer undergoing surgical procedures. Our aim was to evaluate the adherence rate to extended pharmacological thromboprophylaxis after abdominal-pelvic surgery for cancer, before and after an educational intervention program (EIP) geared toward surgeons.
METHODS: Prospective cross-sectional study before and after an EIP aimed for surgeons. All consecutive patients older than 65 years who underwent surgery for abdominal-pelvic neoplasm, at the Hospital Italiano de Buenos Aires, Argentina, between September 2013 and May 2014, were evaluated for inclusion.
RESULTS: A total of 120 patients were included, 60 before and 60 after the EIP aimed for surgeons. None of the initial 60 patients received EP, while 13 (21.6%) of 60 patients received prophylaxis for 28 days (all with colon or rectal cancer) after the intervention. There were no bleeding or death during 90 days of follow-up, and there were 7 of 120 VTE events, none in the group receiving extended thromboprophylaxis.
CONCLUSION: The EIP for the surgical team significantly improved their adherence but only in the colon-rectal surgeries. The adherence to the recommended guidelines is still low. Reasons could be the subjective perception of elevated bleeding risk and the variable grade of recommendation in different guidelines.
© The Author(s) 2015.

Entities:  

Keywords:  cancer; deep vein thrombosis; enoxaparin; neoplasm; pulmonary embolism; surgery; thromboprophylaxis; venous thrombosis

Mesh:

Substances:

Year:  2015        PMID: 25908111     DOI: 10.1177/1076029615583348

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

2.  Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer.

Authors:  M Farzan Rashid; Terri L Jackson; Jheanell A Morgan; Franklin A Dwyer; Beth A Schrope; John A Chabot; Michael D Kluger
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

3.  Population-Based Analysis of Adherence to Postdischarge Extended Venous Thromboembolism Prophylaxis After Colorectal Resection.

Authors:  Anudeep Mukkamala; John R Montgomery; Ana C De Roo; James W Ogilvie; Scott E Regenbogen
Journal:  Dis Colon Rectum       Date:  2020-07       Impact factor: 4.412

4.  A Prospective Observational Study to Determine Rate of Thromboprophylaxis in Oncology Patients Undergoing Abdominal or Pelvic Surgery.

Authors:  Shailesh V Shrikhande; Manish Verma
Journal:  Indian J Surg Oncol       Date:  2021-03-01

5.  Post-discharge venous thromboembolism after pancreatectomy for malignancy: Predicting risk based on preoperative, intraoperative, and postoperative factors.

Authors:  Cary Jo R Schlick; Ryan P Merkow; Anthony D Yang; David J Bentrem
Journal:  J Surg Oncol       Date:  2020-06-12       Impact factor: 3.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.